Skip to content

Enhancing Recovery Capital Amid Opioid Use Disorder Pharmacotherapy: A Pilot Randomized Trial

Developing and Testing an Intervention to Enhance Recovery Capital Amid Opioid Use Disorder Pharmacotherapy: A Pilot Randomized Trial of Linkage to Recovery Support Services

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05245513
Enrollment
145
Registered
2022-02-18
Start date
2025-12-01
Completion date
2027-02-28
Last updated
2025-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Use Disorder

Brief summary

The aims of the current study are to: Aim 1. Develop and refine a novel intervention protocol for individuals receiving medication treatment for opioid use disorder that assertively links them to recovery community centers; Aim 2. Determine the feasibility, acceptability, and preliminary efficacy of assertive linkage to recovery community centers relative to a matched control condition, via a pilot randomized controlled trial; Aim 3. Explain quantitative findings by gaining an in-depth understanding of the intervention's feasibility, acceptability, and preliminary efficacy via qualitative interviews.

Detailed description

This 5-year project seek to advance our understanding of the clinical and public health utility of recovery community centers and help bridge the gap between clinical treatment and community-based recovery support services. As a first step in this work, the investigators will develop and test a new intervention for peer-facilitated assertive linkage of patients receiving opioid use disorder pharmacotherapy to recovery community centers (RCCL), relative to a matched control condition (CC). This study aims to: Aim 1. Develop, manualize, and refine RCCL and CC protocols via stakeholder feedback. RCCL and CC protocols will be developed and manualized by adapting published community-based mutual-help linkage protocols. Upon preliminary manual development, feedback cycles will be conducted with relevant stakeholders (recovery coaches, recovery community center members, pharmacotherapy prescribers) to inform protocol revision, and promote its feasibility, acceptability, and adoptability. Aim 2. Determine the feasibility, acceptability, and preliminary efficacy of RCCL versus CC, via a pilot randomized controlled trial. More specifically, the feasibility of study procedures and RCCL/CC interventions, acceptability of interventions, and preliminary efficacy of RCCL relative to CC will be assessed. Aim 3. Explain quantitative findings by gaining an in-depth understanding of RCCL feasibility, acceptability, and efficacy via qualitative interviews in a subset of RCCL participants, peer facilitators, and linkage managers.

Interventions

BEHAVIORALRecovery Community Center Linkage (RCCL)

A certified recovery coach will meet with participants to educate them on recovery support services, including recovery community centers, and link them to a recovery community center, with the aid of a facilitated connection to a volunteer recovery community center member (e.g., calling a standby peer, scheduling a meet-up at the center). The coach will also provide the participant with a brochure of recovery support resources.

BEHAVIORALControl Condition (CC)

A certified recovery coach will meet with participants to educate them on recovery support services more broadly, including recovery community centers, and will provide them with a brochure of recovery support resources.

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age ≥ 18 years * past-year opioid use disorder diagnosis per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition * currently undergoing outpatient buprenorphine treatment through a provider or program at Massachusetts General Hospital * current residence in Massachusetts

Exclusion criteria

* non-English fluency * active suicidality * neurodevelopmental disorders or neural trauma preventing informed consent * active psychosis * past-year attendance at a recovery community center or recovery support center

Design outcomes

Primary

MeasureTime frameDescription
Use of recovery support servicesFrom the date of linkage manager meeting until the date of month-3 follow up, assessed up to 3 monthsPercent days use of any recovery support services post linkage manager meeting, as assessed via the Timeline Follow Back
Overall intervention feasibilityFrom the date of intervention manual finalization until the date of study completion, assessed up to 48 monthsAssessed via the Feasibility: Intervention Implementation & Training scale average total score. This is a 2-item instrument to assess perceived intervention feasibility. Items are measured on a 6-point Likert scale (Strongly Disagree-Strongly Agree). Score is the calculated mean. Higher scores indicate greater feasibility.
Fidelity: Linkage manager adherenceFrom date of first linkage manager meeting until the date of last linkage manager meeting, assessed up to 36 monthsPercent adherence of linkage managers to intervention protocols, as evaluated by the percentage of sessions that are scored with adequate adherence and assessed by recordings of intervention delivery and adherence evaluation materials developed as part of Aim 1 (e.g., adherence rating scales of critical topics). This is a 14-item instrument evaluating the extensiveness of linkage managers' delivery of critical intervention topics. Items are measured on a 5-point Likert scale (Not at all - Extensively). Score is the calculated mean. Total scores range from 1 to 5, with scores \> 3 indicating adequate adherence.
Overall intervention acceptabilityMonth 1Assessed via 1 single-item statement addressing the the acceptability of the intervention. The item is measured on a 6-point Likert scale (Strongly Disagree - Strongly Agree). Higher scores indicate greater acceptability.
Overall intervention satisfactionMonth 1Assessed via the Client Satisfaction Questionnaire-8 (CSQ8) total score. This is an 8 item measure of client satisfaction with services. Total scores range from 8 to 32, with higher scores indicating greater satisfaction.
Recovery community center attendanceFrom the date of linkage manager meeting until the date of month-3 follow up, assessed up to 3 monthsPercent of participants who attended a recovery community center 1+ time post linkage manager meeting, as assessed via the Timeline Follow Back
Overall recruitment feasibilityThrough study completion, ~3 years from recruitment initiationNumber of participants successfully recruited within allotted recruitment time frame (\ 3 years)

Secondary

MeasureTime frameDescription
Feasibility of peer facilitator meet-upsMonth 1; Month 3Percent of peer facilitator meet-ups occurring within 2 weeks of participant's linkage manager meeting
Intervention appropriatenessMonth 1Assessed via the Intervention Appropriateness Measure (IAM; adapted for study parameters) average total score. This is a 4-item instrument to assess perceived intervention appropriateness. Items are measured on a 5-point Likert scale (Strongly Disagree-Strongly Agree). Score is the calculated mean. Higher scores indicate greater appropriateness.
Intervention helpfulnessMonth 1; Month 3Assessed via 4 single-item statements addressing the intervention's helpfulness in general and helpfulness to supporting treatment and opioid use disorder recovery. Items are measured on a 6-point Likert scale (Strongly Disagree-Strongly Agree). Score is the response for each item. Higher scores indicate greater helpfulness.
Change in recovery capital from baseline to Month 3Baseline; Month 1; Month 3Assessed via the REC-CAP Inventory total score. Scores range from -100 to +100, with higher scores indicating greater recovery capital.
Participant retentionFrom the date of first participant enrollment in the trial to the date of study completion, up to 42 monthsPercent of enrolled participants who complete Month 3 Follow-Up

Countries

United States

Contacts

Primary ContactLauren A Hoffman, PhD
lhoffman1@mgh.harvard.edu(617) 643-4690
Backup ContactJohn F Kelly, PhD
jkelly11@mgh.harvard.edu(617) 643-1980

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026